Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iafrate

Showing results (431-440 of 655) with videos related to

Pageof 66
Sort By:
Neuro-Oncology|November 30, 2018
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse gliomaTejus A Bale, Justin T Jordan, Otto Rapalino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western populationScott J Rodig, Mari Mino-Kenudson, Sanja Dacic, et al.
Critical Reviews in Oncology/Hematology|April 15, 2023
The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectivesCatia Carconi, Micaela Cerreti, Michela Roberto, et al.
Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cell Reports. Medicine|December 10, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cancer Research|May 3, 2008
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitorsUltan McDermott, A John Iafrate, Nathanael S Gray, et al.
Cancer Research|October 15, 2009
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokersLynette M Sholl, Beow Y Yeap, A John Iafrate, et al.
Blood Advances|September 29, 2021
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivitySarah B Mueller, Paola Dal Cin, Long P Le, et al.
European Radiology|July 6, 2020
Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosisMarco Francone, Franco Iafrate, Giorgio Maria Masci, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Pageof 66

Showing results (431-440 of 655) with videos related to

Sort By:
Pageof 66
Neuro-Oncology|November 30, 2018
Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse gliomaTejus A Bale, Justin T Jordan, Otto Rapalino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western populationScott J Rodig, Mari Mino-Kenudson, Sanja Dacic, et al.
Critical Reviews in Oncology/Hematology|April 15, 2023
The management of oligometastatic disease in colorectal cancer: Present strategies and future perspectivesCatia Carconi, Micaela Cerreti, Michela Roberto, et al.
Medrxiv : the Preprint Server for Health Sciences|March 18, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cell Reports. Medicine|December 10, 2024
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunityAlex L Roederer, Yi Cao, Kerri St Denis, et al.
Cancer Research|May 3, 2008
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitorsUltan McDermott, A John Iafrate, Nathanael S Gray, et al.
Cancer Research|October 15, 2009
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokersLynette M Sholl, Beow Y Yeap, A John Iafrate, et al.
Blood Advances|September 29, 2021
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivitySarah B Mueller, Paola Dal Cin, Long P Le, et al.
European Radiology|July 6, 2020
Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosisMarco Francone, Franco Iafrate, Giorgio Maria Masci, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerSai-Hong Ignatius Ou, Lyudmila Bazhenova, D Ross Camidge, et al.
Pageof 66